News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Pablo Mando: T-DXd demonstrated benefit over Capecitabine and Taxane in HR+/HER2- MBC
Carlos Barrios/lacogcancerresearch.org
May 15, 2025, 14:51

Pablo Mando: T-DXd demonstrated benefit over Capecitabine and Taxane in HR+/HER2- MBC

Pablo Mando, Editor-in-Chief of Oncologia Clínica, shared a post on X:

“Great presentation by Carlos Barrios reporting that T-DXd demonstrated a clinically meaningful efficacy benefit over both TPC subgroups (capecitabine and taxane), with improved PFS, ORR, DOR, and PFS2 in DB-06.”

Pablo Mando: T-DXd demonstrated benefit over Capecitabine and Taxane in HR+/HER2- MBC

Paolo Tarantino, Advanced Research Fellowship at Dana-Farber Cancer Institute and Harvard Medical School, reshared the post on X, adding:

“Seems to confirm a frequent empirical finding:

capecitabine > taxanes for treating HR+/HER2- MBC (with T-DXd outperforming both).”

More posts featuring Paolo Tarantino.

cancer capecitabine Dana-Farber Cancer Institute DB-06 DOR fight against cancer Global fight against cancer Harvard Medical School MBC metastatic breast cancer OncoDaily Oncologia Clínica Oncology ORR pablo mando Paolo Tarantino PFS PFS2 T-Dxd taxane
Special Coverage
Science
May 15, 2025, 14:55
Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Blog
May 15, 2025, 14:51
Pablo Mando: T-DXd demonstrated benefit over Capecitabine and Taxane in HR+/HER2- MBC
Blog
May 15, 2025, 14:41
Patrick Hwu: The Heart of Moffitt Is Each of Our Team Members
Blog
May 15, 2025, 14:36
Vincent Rajkumar Presenting at the Spring ECOG Conference in Tampa
Blog
May 15, 2025, 14:26
Robert F. Kennedy, Jr.: Gain-of-function research has no place in a civilized society
Blog
May 15, 2025, 14:19
FDA Approves the First Oral Treatment for Pheochromocytoma and Paraganglioma - FDA Oncology
Blog
May 15, 2025, 14:12
Role of Technical Partners in Strengthening Urban Cancer Care - City Cancer Challenge
Cancer Types
May 15, 2025, 14:10
Craniopharyngioma: Symptoms, Diagnosis, Treatment, and 2025 Breakthroughs in Targeted Therapy and Precision Care
Blog
May 15, 2025, 13:38
One of the Least Talked about and Misunderstood Cancers in Our Communities - Medicaid Cancer Foundation
Oncolibrary
May 15, 2025, 13:36
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer
Science
May 15, 2025, 13:36
Hagop Kantarjian: Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements
Blog
May 15, 2025, 13:30
The Pivotal Role of Cancer Nurses in Shaping the Future of Oncology Care - European Oncology Nursing Society